Samuel D. Riccitelli served as Signal Genetics President and CEO and as a director on the company’s board of directors from October 2012 until February 2017, when the company was acquired by miRagen Therapeutics in a reverse merger transaction. From July 2011 to October 2012, Sam was an independent consultant. From October 2001 to June 2011, he served as the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic services company focused on the needs of community hematologists and oncologists. From 1995 to 2001, Sam served in a number of positions for Becton, Dickinson and Company, most recently as a vice president and general manager and as a board member for the venture capital fund, BD Ventures, LLC. From 1989 to 1994, he served in a number of positions at Puritan-Bennett Corporation, including most recently as general manager. He also served on the board of directors of Exagen Diagnostics, Inc. from October 2011 to September 2014. Sam received a B.A. in Biology from Washington and Jefferson College and a M.S. in Engineering from The University of Texas in Mechanical & Biomedical Engineering.
Financing Strategies for Precision Medicine Ventures
9:05 AM - 9:55 AM